

Remarks:

With the above-requested amendments made in view of the election of Group I, applicants have withdrawn claims to the subject matter relating to the combinations of separate H<sub>3</sub> and m<sub>2</sub> antagonists in claim 3-13, and to the kits of claim 16.

Applicants traverse the restriction requirement with respect to claim 15 insofar as it relates to compositions comprising dual H<sub>3</sub>/m<sub>2</sub> antagonists in combination with acetylcholinesterase inhibitors, since said combinations are part of Group I.


Applicants have amended claims 14 and 15 to delete reference to the combinations of separate H<sub>3</sub> and m<sub>2</sub> antagonists in view of the restriction requirement.

In response to the requirement to elect a species, applicants hereby elect the dual H<sub>3</sub>/m<sub>2</sub> species of compound 11 shown on page 4 (in claim 2, compound 11 is the last compound on page 35). The elected species of acetylcholinesterase inhibitor is tacrine (see page 28, line 13).

No change in inventorship is required in view of the election of Group I.

Applicants look forward to an early examination on the merits.

Respectfully submitted,



Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067